Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 3 2

Status

Recruiting 6Active not recruiting 4Completed 3Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Neoplasms 13Prostatic Neoplasms 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Carcinoma, Hepatocellular 11Multiple Myeloma 10Leukemia, Myeloid, Acute 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 6Uterine Cervical Neoplasms 5Recurrence 5Glioblastoma 5Esophageal Squamous Cell Carcinoma 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Lymphoma, Follicular 4

Interventions

Trastuzumab 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × HER2-positive Breast Cancer × Clear all
NCT05698186 2023-01-26

Thero2-01S22 in HER2-positive Breast Cancer

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting
320 enrolled
Breast

HER2-positive Breast Cancer

NCT05388500 2022-05-27

PHARE-C

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting
800 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡